21 Feb 2018 09:37
INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 31 January 2018
Net Assets | £233m |
Net Assets per share | 619p |
Share price | 614p |
Total value of unquoted investments | £20m |
Total number of portfolio companies | 92 |
Dividend | 4% of NAV per annum |
Top Ten Quoted Investments
Company Name | % NAV |
Biogen | 6.2 |
Celgene | 4.6 |
Nektar | 4.4 |
Regeneron | 4.0 |
Exelixis | 3.8 |
Acadia | 3.7 |
Vertex | 3.6 |
Adamas | 3.6 |
Genmab | 3.1 |
Gilead | 3.1 |
----------- | |
Total | 40.1 |
Geographical Allocation | % NAV |
US & Canada | 91 |
Europe & UK | 9 |
----------- | |
Total | 100 |
Quoted/Unquoted Allocation | % NAV |
Quoted | 92 |
Unquoted | 8 |
----------- | |
Total | 100 |
NAV % Market Cap | % NAV |
Large Cap >USD10BN | 40 |
Mid Cap =USD1-10BN | 34 |
Small Cap | 26 |
----------- | |
Total | 100 |
NAV % by Therapeutic Areas | % NAV |
Oncology | 38 |
Rare diseases | 14 |
CNS | 14 |
Inflammation | 8 |
Ophthalmology | 6 |
Metabolic | 5 |
Infectious Diseases | 4 |
Medtech | 2 |
Other | 9 |
----------- | |
Total | 100 |
BNP Paribas Secretarial Services Limited
Company Secretary
21 FEBRUARY 2018